Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy

被引：3

作者：

Hoyle, Christopher ^{[1
]}

Dyer, Matthew ^{[1
]}

机构：

[1] AstraZeneca, Acad House,136 Hills Rd, Cambridge CB2 8PA, Cambs, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 05期

关键词：

D O I：

10.1016/j.jtho.2018.02.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E83 / E84

页数：2

共 50 条

[11] Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada [J].

Yong-Jin Kim ;

Mark Oremus ;

Helen H. Chen ;

Thomas McFarlane ;

Danielle Fearon ;

Susan Horton .

PharmacoEconomics, 2021, 39 :537-548

[12] Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China [J].

Xu, Xinglu ;

Fang, Nan ;

Li, Huanan ;

Liu, Yanyan ;

Yang, Fan ;

Li, Xin .

ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (09)

[13] Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia [J].

Khoo, Terence ;

Gao, Lan .

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (03) :415-423

[14] EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations [J].

Kim, Edward S. ;

Melosky, Barbara ;

Park, Keunchil ;

Yamamoto, Nobuyuki ;

Yang, James C-H .

FUTURE ONCOLOGY, 2021, 17 (18) :2395-2408

[15] EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome [J].

Tiefenbacher, Andreas ;

Pirker, Robert .

JOURNAL OF THORACIC DISEASE, 2017, 9 (11) :4208-4211

[16] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis [J].

Aguilar-Serra, Javier ;

Gimeno-Ballester, Vicente ;

Pastor-Clerigues, Alfonso ;

Milara, Javier ;

Marti-Bonmati, Ezequiel ;

Trigo-Vicente, Cristina ;

Alos-Alminana, Manuel ;

Cortijo, Julio .

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) :853-863

[17] Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer [J].

Bridges, John F. P. ;

de la Cruz, Marie ;

Pavilack, Melissa ;

Flood, Emuella ;

Janssen, Ellen M. ;

Chehab, Nabil ;

Fernandes, Ancilla W. .

FUTURE ONCOLOGY, 2019, 15 (34) :3895-3907

[18] Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer [J].

Verhoek, Andre ;

Cheema, Parneet ;

Melosky, Barbara ;

Samson, Benoit ;

Shepherd, Frances A. ;

de Marinis, Filippo ;

John, Thomas ;

Wu, Yi-Long ;

Heeg, Bart ;

Van Dalfsen, Nadia ;

Bracke, Benjamin ;

Miranda, Miguel ;

Shaw, Simon ;

Moldaver, Daniel .

PHARMACOECONOMICS-OPEN, 2023, 7 (03) :455-467

[19] Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer [J].

Andre Verhoek ;

Parneet Cheema ;

Barbara Melosky ;

Benoit Samson ;

Frances A. Shepherd ;

Filippo de Marinis ;

Thomas John ;

Yi-Long Wu ;

Bart Heeg ;

Nadia Van Dalfsen ;

Benjamin Bracke ;

Miguel Miranda ;

Simon Shaw ;

Daniel Moldaver .

PharmacoEconomics - Open, 2023, 7 :455-467

[20] First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status [J].

Takamizawa, Shigemasa ;

Okuma, Yusuke ;

Kato, Yasuhiro ;

Hakozaki, Taiki ;

Kitagawa, Shingo ;

Zenke, Yoshitaka .

FUTURE ONCOLOGY, 2021, 18 (03) :291-300

← 1 2 3 4 5 →